Clinical trial
Open access
Sep 2026
Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAFV600E- or BRAFInsT-Mutant Brain Tumors: PNOC002
Vemurafenib showed efficacy in children with recurrent or progressive BRAFV600E-mutant brain tumors with acceptable toxicity, however, the rebound rate of 23% warrants further investigation.
T. Nicolaides, R. Hoogendijk, Marie Jaeger-Krause et al.
· JCO Precision Oncology · 0 citations